VYJUVEK

This brand name is authorized in United States.

Active ingredients

The drug VYJUVEK contains one active pharmaceutical ingredient (API):

1	Beremagene geperpavec UNII AQN7K24KQU - BEREMAGENE GEPERPAVEC
	Beremagene geperpavec is a gene therapy based on an engineered, replication-defective herpes simplex virus 1 (HSV-1) encoded with COL7A1 gene, addressing the underlying genetic cause of dystrophic epidermolysis bullosa. The HSV-1 vector belongs to the human herpes virus (HHV) family of double-stranded DNA viruses. Upon cutaneous application to the wounds, beremagene geperpavec can transduce both keratinocytes and fibroblasts.
	Read more about Beremagene geperpavec

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VYJUVEK Suspension and gel for gel	MPI, EU: SmPC	European Medicines Agency (EU)
VYJUVEK Kit, biological suspension and excipient gel for topical application	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D03AX16		D Dermatologicals → D03 Preparations for treatment of wounds and ulcers → D03A Cicatrizants → D03AX Other cicatrizants
Discover more medicines within D03AX16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	82194-001, 82194-501, 82194-510